Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px
Document › Details

Kiadis Pharma N.V.. (10/18/18). "Press Release: Kiadis Pharma Launches a Private placement of approximately 3.7 Million New Shares [Not for United States, Australia, Canada, Japan, South Africa or any other jurisdiction where unlawful]". Amsterdam.

Organisations Organisation Kiadis Pharma N.V. (Euronext: KDS)
  Group Kiadis (Group)
  Organisation 2 Optimum Strategic Communications
Products Product ATIR101™ (Kiadis)
  Product 2 venture capital
Index term Index term Kiadis–SEVERAL: investment, 201810 private placment €31.2m with 3.9m new shares at €8/share
Persons Person Hård, Karl (Kiadis 201709–201812 Head IR + Communications LEFT 1/19 before Redx Pharma + AstraZeneca)
  Person 2 Clark, Mary (Optimum Strategic Communications 201710 before Hume Brophy + M:Communications + Capital MSL)
     


   
Record changed: 2019-03-08

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Kiadis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top